Drug utilization study in patients affected with COVID-19 in a dedicated COVID hospital

Background: There exists a treatment dilemma regarding the optimal and effective use of therapeutic drugs (hydroxychloroquine/chloroquine/azithromycin) for COVID-19. Furthermore, with changing guidelines, the data on drug utilization patterns across India are limited. Hence, this study was conducted to assess the prescription pattern and drug utilization trends in COVID-19 patients with the aim to study the drug utilization pattern in patients affected with COVID-19 in a dedicated COVID-19 hospital. Aims and Objectives: The objectives of the study are as follows: (1) To study drug utilization patterns according to the severity of the disease. (2) To study the prevalence of adverse drug reactions (ADRs). Materials and Methods: Data were collected retrospectively from 100 medical records of patients 18 years irrespective of sex admitted in the COVID ward and ICU of a dedicated COVID hospital from May to August 2020. Pregnant and lactating women were excluded from the study. ADRs reported were also analyzed. Results: About 71% were mild in this study, 18% were moderate, and 11% were severe COVID-19 patients. Overall, the most common drugs prescribed were multivitamins, followed by pantoprazole, paracetamol, and azithromycin. Hydroxychloroquine was prescribed in 22%, favipiravir in 7%, and remdesivir in 3% of cases. The majority of moderate COVID patients received injectables piperacillin-tazobactam, methylprednisolone, and enoxaparin. The mean number of medications, duration of admission, and number of days on oxygen were higher and significant in moderate compared to mild and severe COVID patients. Overall, ADRs were encountered in 9% of cases. Conclusion: The prescribed pattern of drugs was by the national standard guidelines. Multivitamins, followed by pantoprazole, paracetamol, and azithromycin dominated the prescription pattern. Polypharmacy was encountered, which needs to be addressed for the rational use of drugs.

Implementation of indication-based antibiotic order sentences improves antibiotic use in emergency departments.

INTRODUCTION: Prior data have suggested that suboptimal antibiotic prescribing in the emergency department (ED) is common for uncomplicated lower respiratory tract infections (LRTI), urinary tract infections (UTI), and acute bacterial skin and skin structure infections (ABSSSI). The objective of this study was to measure the effect of indication-based antibiotic order sentences (AOS) on optimal antibiotic prescribing in the ED. METHODS: This was an IRB-approved quasi-experiment of adults prescribed antibiotics in EDs for uncomplicated LRTI, UTI, or ABSSSI from January to June 2019 (pre-implementation) and September to December 2021 (post-implementation). AOS implementation occurred in July 2021. AOS are lean process, electronic discharge prescriptions retrievable by name or indication within the discharge order field. The primary outcome was optimal prescribing, defined as correct antibiotic selection, dose, and duration per local and national guidelines. Descriptive and bivariate statistics were performed; multivariable logistic regression was used to determine variables associated with optimal prescribing. RESULTS: A total of 294 patients were included: 147 pre-group and 147 post-group. Overall optimal prescribing improved from 12 (8%) to 34 (23%) (P < 0.001). Individual components of optimal prescribing were optimal selection at 90 (61%) vs 117 (80%) (P < 0.001), optimal dose at 99 (67%) vs 115 (78%) (P = 0.036), and optimal duration at 38 (26%) vs 50 (34%) (P = 0.13) for pre- and post-group, respectively. AOS was independently associated with optimal prescribing after multivariable logistic regression analysis (adjOR, 3.6; 95%CI,1.7-7.2). A post-hoc analysis showed low uptake of AOS by ED prescribers. CONCLUSIONS: AOS are an efficient and promising strategy to enhance antimicrobial stewardship in the ED.

Prescribing Trends in Psychotropic Medications Among Outpatients of a Latin American Healthcare Setting: A Five-Year Retrospective Study.

Introduction Mental health problems affect millions worldwide, and the prescription of psychotropic drugs is increasing globally. The World Health Organization (WHO) has emphasized the need for proper monitoring of psychotropic drug prescriptions. This study aims to characterize and find trends in the prescription of psychotropics in a Latin American General Hospital. Methods The study analyzed the dispensation of psychotropic prescriptions to outpatients at three pharmacies in the central headquarters of Hospital Clínica Bíblica in San José, Costa Rica, from 2017 to 2021. Psychotropic drugs were classified by the Anatomical Therapeutic Chemical (ATC) code, and the amount of each medication dispensed was standardized using the defined daily dose per 10,000 population per day metric. Patients' ages were categorized into four groups: under 18 years, 18 to 39 years, 40 to 64 years, and 65 years and above. The prescriptions were categorized according to medical specialty. Regression analyses were performed to determine the significance of trends observed in the data Results A total of 5793 psychotropic prescriptions were recorded. The average age of the patients was 58 years. The total consumption of psychotropics decreased by 33.94% from 2017 to 2021, with the most significant decline until 2020. However, there was an increase in consumption in 2021. Clonazepam was the most consumed medication, followed by bromazepam and alprazolam, which was the sole drug to exhibit an escalation in usage between 2017 and 2021. Regression analysis showed that only alprazolam and zopiclone had statistically significant trends. The highest number of prescriptions was dispensed to patients aged between 40 and 64 years, followed by those aged over 65 years. Anxiolytics were also the most commonly prescribed group of drugs. General medicine (20.22%), psychiatry (19.95%), and internal medicine (12.73%) were the primary specialties that prescribed psychotropic; 38.6% of prescriptions were associated with the 10th decile of patients, and 44.9% of prescriptions were issued by the 10th decile of physicians.  Conclusion The consumption of psychotropic drugs decreased from 2017 to 2020 but increased in 2021, with alprazolam being the only drug that showed an increase in consumption throughout the entire period. General practitioners and psychiatrists were found to be the specialties that most commonly prescribe these medications. The study found significant trends only for the consumption of alprazolam and zopiclone and for prescription patterns among psychiatrists and internal medicine physicians.

A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver.

Background Medications for the treatment of opioid use disorder (MOUD) are effective evidence-based strategies to reduce opioid overdose deaths. Strategies to optimize MOUD availability and uptake are needed. Objective We aim to describe the spatial relationship between the estimated prevalence of opioid misuse and office-based buprenorphine access in the state of Ohio prior to the removal of the Drug Addiction Treatment Act of 2000 (DATA 2000) waiver requirement. Methods We conducted a descriptive ecological study of county-level (N=88) opioid misuse prevalence and office-based buprenorphine prescribing access in Ohio in 2018. Counties were categorized into urban (with and without a major metropolitan area) and rural. The county-level prevalence estimates of opioid misuse per 100,000 were derived from integrated abundance modeling. Utilizing data from the Ohio Department of Mental Health and Addiction Services, as well as the state's Physician Drug Monitoring Program (PDMP), buprenorphine access per 100,000 was estimated by the number of patients in each county that could be served by office-based buprenorphine (prescribing capacity) and the number of patients served by office-based buprenorphine (prescribing frequency) for opioid use disorder. The ratios of opioid misuse prevalence to both prescribing capacity and frequency were calculated by county and mapped. Results Less than half of the 1,828 waivered providers in the state of Ohio in 2018 were prescribing buprenorphine, and 25% of counties had no buprenorphine access. The median estimated opioid misuse prevalence and buprenorphine prescribing capacity per 100,000 were highest in urban counties, particularly those with a major metropolitan area. Although the median estimated opioid misuse prevalence was lower in rural counties, all counties in the highest quartile of estimated misuse prevalence were rural. In addition, the median buprenorphine prescribing frequency was highest in rural counties. While the ratio of opioid misuse prevalence to buprenorphine prescribing capacity was lowest in urban counties, the ratio of opioid misuse prevalence to buprenorphine prescribing frequency was lowest in rural counties. Opioid misuse prevalence and buprenorphine prescribing frequency demonstrated similar spatial patterns, with highest levels in the southern and eastern portions of the state, while office-based buprenorphine prescribing capacity did not. Conclusion Urban counties had higher buprenorphine capacity relative to their burden of opioid misuse; however, access was limited by buprenorphine prescribing frequency. In contrast, in rural counties, a minimal gap was evident between prescribing capacity and frequency, suggesting that buprenorphine prescribing capacity was the major factor limiting access. While the recent deregulation of buprenorphine prescribing should help improve buprenorphine access, future research should investigate whether deregulation similarly impacts buprenorphine prescribing capacity and buprenorphine prescribing frequency.

An observational study of the cause and frequency of prescription rework in community pharmacies.

BACKGROUND: When prescriptions are being processed in pharmacies, 'rework' is a phenomenon where an activity occurs that requires the return to a prior procedural step in the process for correction. To date, little is known regarding rework prevalence in community pharmacies or how this might be minimised. AIM: To evaluate the cause and frequency of prescription rework in community pharmacies. METHOD: A list of reworks was designed for community pharmacists to self-record prescription rework instances and causes in their workplace across a two-week period. Community pharmacists in Ireland were recruited via convenience sampling and snowballing. Descriptive statistics were used to assess rework frequency according to the various causes, as well as the pharmacist and pharmacy characteristics. RESULTS: Eight pharmacists participated, recording 325 reworks across 92.9% of the 65 study days (mean 5 reworks/day). The pharmacists' mean ranged from 1.82 to 15 reworks/day. Pharmacists and pharmacy technicians alone or together were involved in 72.3% of reworks. The three most common rework categories were involving labelling errors (22.8%), prepared prescriptions which necessitated opening and repackaging (15.1%), and medication owings to patients (13.9%). CONCLUSION: This study reveals that prescription rework occurs frequently in community pharmacies and has provided an indication of some of the main causes. These findings demonstrate areas where pharmacy staff can address rework and should aid the development of approaches to minimise rework in future - thus decreasing workload and facilitating more time for community pharmacy staff to focus on providing patient care.

The impact of COVID-19 on electronic repeat dispensing (eRD) in general practice.

BACKGROUND: Electronic repeat dispensing (eRD) has been part of the community pharmacy contact since 2005 and a requirement in the General Medical Services contract since 2019. NHS England highlights benefits of eRD as increased efficiency in general practice of 2.7 million hours annually if 80% of all repeat prescriptions are issued as eRD. Despite clear benefits to patients, community pharmacies and general practices, the uptake of eRD remains low and variable across general practices in West Yorkshire, UK. OBJECTIVES: To investigate the impact of COVID-19 on eRD in general practice and understand the key enablers to its uptake. METHODS: A 19-item questionnaire was developed and piloted during cognitive interviews. A cross-sectional survey was conducted via emails to general practices in West Yorkshire, UK, between July 2020 and November 2020. RESULTS: Sixty-seven complete responses were received (23 pharmacists, 21 practice managers, 11 general practitioners, seven pharmacy technicians, four advanced practitioners, one prescription clerk). 59% of respondents were aware of eRD uptake in their surgery (mean value 4.56% ± 0.229%). Higher uptake of eRD was demonstrated where the general practice integrated eRD into routine workflows during the repeat prescription reauthorisation process (P < 0.001) and where an eRD service lead is nominated (P = 0.04). CONCLUSION: Utilising eRD in the respective practices should be considered due to potential efficiency gains and the increase in average eRD utilisation observed in the study participating general practices was from 7.2% average uptake in March 2020 to 10.4% November 2020, as the response to COVID-19. The stated benefits of eRD by NHS England of 2.7 million hours per annum predates the roll out of electronic transmission of prescriptions suggesting further research is needed to quantify the efficiency gains in present NHS general practice environments.

Optimizing lipid management-impact of the COVID 19 pandemic upon cardiovascular risk in England.

BACKGROUND: We sought to understand the impact of the COVID-19 pandemic on lipid-lowering therapy prescribing as a potential cause of the excess cardiovascular mortality seen post-pandemic in England. We examined temporal changes over 3 years in the prescribing of high-intensity and non-high-intensity statin therapy and ezetimibe. SOURCES OF DATA: We utilized data available via the National Health Service (NHS) Business Services Authority (NHSBSA) Information Services Data Warehouse, extracting 3 monthly data from October 2018 to December 2021 on high- and low-intensity statin and ezetimibe prescribing, (commencement, cessation or continuation) through each time period of study and those before, and after, the period of interest. AREAS OF AGREEMENT: Optimizing lipid management is a key component of the NHS Long Term Plan ambition to reduce deaths from cardiovascular disease, stroke and dementia. AREAS OF CONTROVERSY: The COVID-19 pandemic and associated lockdown have seen a significant reduction in prescribing of lipid-lowering therapies. If cardiovascular risk is not to worsen in the forthcoming years, urgent action is needed to ensure that the impact of the pandemic upon optimization of cholesterol and the historical undertreatment of cholesterol is reversed and improved. AREAS TIMELY FOR DEVELOPING RESEARCH: Prescription data available via NHSBSA can support our understanding of the implications of policy and behaviour and highlight the impact of guidelines in practise. GROWING POINTS: Understanding the impact of the COVID-19 pandemic upon cholesterol management and the opportunities for newer lipid-lowering therapies delivered using a population health approach have the potential to enhance lipid-lowering and improve cardiovascular mortality and morbidity and reduce health inequalities.

The opioid epidemic.

An opioid epidemic has been happening across the world since the 1990s and continues impact individuals, families, communities and societies around the globe. The epidemic has evolved from heroin misuse to the use of synthetic opioids that are easily manufactured and are readily available. Reasons for the continuing opioid epidemic are complex, and include factors related to mental health, addiction, chronic pain relief, and, now, the COVID-19 pandemic. Women have been disproportionally affected by the opioid epidemic and the physical and biosocial effects of opioid use specific to women are an important consideration for healthcare providers. Recent data show that the effects of the opioid epidemic on rates of opioid use disorder (OUD), overdoses, and the economy continue to rise, despite global efforts to understand the drivers and develop effective prevention and intervention strategies, programs, and policies.

Screening of Potential Inhibitors Against SARS-CoV-2 Based on Prescription Mining and Molecular Dynamics Simulations

Objective To detect the active ingredients in the traditional Chinese medicine prescription and its molecular mechanisms against SARS-CoV-2 by prescription mining and molecular dynamics simulations. Methods Herein, prescription mining and virtual screening of drugs were performed to screen the potential inhibitors against SARS-CoV-2. Molecular docking and molecular dynamics (MDs) simulations were further performed to explore the molecular recognition and inhibition mechanism between the potential inhibitors and SARS-CoV-2. Results The natural compounds library was constructed by 143 prescriptions of traditional Chinese medicine, which contained 640 natural compounds. Ten compounds were screened out from the natural compounds library. Among the 10 compounds, 23-trans-p-coumaryhormentic acid, the main active constituent of the Loquat leaf, showed the best binding affinity targeting the recognizing interface of SARS-CoV-2 S protein/ACE2. Upon binding 23-trans-p-coumaryhormentic acid, the key interactions between SARS-CoV-2 S protein and ACE2 were almost interrupted. Conclusion Ten compounds targeting SARS-CoV-2 S protein/ACE2 interface were screened out from natural compound library. And we inferred that 23-trans-p-coumaryhormentic acid is a potential inhibitor against SARS-CoV-2, which would contribute to the development of the antiviral drug for SARS-CoV-2. © 2022 Institute of Biophysics,Chinese Academy of Sciences. All rights reserved.

Association between self-reported evidence-based medicine competencies and prescribing of drugs without scientific evidence against mild COVID-19 among recently graduated physicians in Peru.

Objective: To evaluate the association between self-rated evidence-based medicine (EBM) competencies and the prescription of drugs without scientific evidence against mild COVID-19 (present with any of the signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnea, or abnormal chest imaging) among recently graduated physicians in Peru. Methods: We conducted an analytical cross-sectional study where we evaluated a non-probability sample of recently graduated physicians during June and July 2021 (end of second wave of COVID-19 in Peru). Self-rated EBM competencies were assessed by four domains (formulation of a clinical question, search, analysis, and application) using a Likert scale with scores from zero to four ("Very inadequate" = 0, to "Very Adequate" = 4), it was considered as "Adequate" if the score was three or four. In addition, the variable "General competence on EBM" was rated as "Adequate" if in all domains evaluated it presented an adequate self-rating. For the outcome, drug prescription, we considered the use of ivermectin, azithromycin, other antibiotics, hydroxychloroquine, dexamethasone, and anticoagulants (drugs with no efficacy demonstrated for patients with mild COVID-19). To assess the association, we used Poisson regression models with robust variances and obtaining crude (cPR) and adjusted (aPR) prevalence ratios with their 95% confidence intervals (95%CI). Results: Of a total of 239 physicians included 70.7% prescribed at least one drug without scientific evidence. A total of 51.1% reported adequate ratings in all evaluated domains of EBM. Self-rating the "Clinical Question Formulation" competency as adequate was associated with a lower frequency of prescribing medications for mild COVID-19 (aPR: 0.93; 95% CI: 0.91-0.95). While self-rating as adequate the competency of "Identify possible implications of investigations" was associated with an increase in the prescription of such drugs (aPR: 1.14; 95% CI: 1.09-1.20). Additionally, self-rating all domains as adequate were associated with less prescription (aPR: 0.93; 95% CI: 0.90-0.96). Conclusion: Seven out of ten recently graduated physicians prescribed some type of medication without scientific evidence to treat patients with mild COVID-19. Having adequate self-perceived EBM competencies was associated with a lower frequency of prescribing medications without scientific evidence to manage patients with mild COVID-19.

Pharmacotherapy analysis for hospitalized patients with COVID-19 (prescriptions, costs and outcomes)

Background: The COVID-19 pandemic has caused many economic problems worldwide, in Iran as well, causing Hospitals to face many financial problems. Objectives: Based on documented data on pharmacotherapy, costs, and its effectiveness, this study aimed to analyze the costs and outcomes of hospitalized patients with COVID-19 under pharmacotherapy in Iran. Methods: This research was a retrospective analytical descriptive study. Relevant data of the COVID-19 hospitalized patients' were extracted from the Hospital's Medical Records Department. All items of direct medical costs, such as visits, nursing services, consuming materials, laboratories, imaging, medical operations, medications, and beds, were extracted by reviewing COVID-19 hospitalized patients' files in different wards of the Shohada Ashayer Hospital in Khorramabad city in 2021. Results: A total of 399 patients were examined in this study. The total direct medical costs per patient was 338.63 US$. Of note, the highest cost was related to medicine (32.56%), more than the cost of bed (22.77%). The most commonly used drugs were Lopinavir (95%) and Azithromycin (90%), and the highest medicine cost per patient was related to Immunoglobulin (64.32 US$) and Remdesivir (46.91 US$). Conclusion: Medicine and hospitalization costs accounted for the largest share of the total treatment costs of patients. Therefore, reducing bed costs requires home treatments and outpatient injections. Furthermore, due to rising drug costs, prescriptions should be based on standard treatment protocols.

All children left behind: drug adherence and the COVID-19 pandemic

We study the effect of the COVID-19 pandemic on chronic disease drug adherence. Focusing on asthma, we use a database that tracks the vast majority of prescription drug claims in the U.S. from 2018 to 2020. Using a difference-in-differences empirical specification, we compare monthly drug adherence in 2019 and 2020 for the set of chronic patients taking asthma medication before the onset of the pandemic. We find that the pandemic increased adherence for asthmatic adults by 10 percent. However, we find a sustained decrease in pediatric drug adherence that is most severe for the youngest children. By the end of 2020, drug adherence fell by 30 percent for children aged 0 to 5, by 12 percent for children aged 6 to 12, and 5 percent for children aged 13 to 18. These negative effects are persistent regardless of changes in medical need, socioeconomic factors, insurance coverage and access to health services. We provide suggestive evidence that the observed pediatric changes are likely driven by parental inattention.

Anti-COVID-19 Traditional Chinese Medicine Database

Background: Novel coronavirus pneumonia COVID-19 has become a serious threat to human health. Traditional Chinese Medicine (TCM) has a good clinical effect in the treatment of COVID-19, with a high effective rate and a low rate of turning to the serious stage. Objective(s): We generated the web-accessed anti-COVID-19 TCM database to provide the anti-COVID-19 TCM information to develop effective drugs for the treatment of COVID-19. Method(s): Herein, we collected these prescriptions data by querying the CNKI and Wanfang Chinese da-tabases, the clinical guidance for COVID-19 pneumonia diagnosis and treatment, and further set up the web-accessible anti-COVID-19 TCM database. Result(s): Altogether, 293 different prescriptions are applied in four different COVID-19 stages of treat-ment, and the prevention of COVID-19 is composed of 452 TCM components. Conclusion(s): The database provides comprehensive information for anti-COVID TCM and thus would help to investigate novel ways to develop new anti-COVID-19 agents.Copyright © 2022 Bentham Science Publishers.

Work efficiency, physical and neurological dysfunction associated with the number of personal protective equipment-donned by doctors working hours in a COVID care center at Puducherry

Background:Personal Protective Equipment (PPE) forms a very important part of the protective armour for the frontline warriors in this battle against the COVID-19 pandemic. Present study aimed to assess the work efficiency, physical and neurological dysfunction associated with the number of Personal Protective Equipment-donned working hours by Doctors in a Covid care center. Material & Method: This cross-sectional study was conducted among the doctors working in COVID ward of AVMCH during the June 2021 to November 2021. All the doctors worked in COVID-19 ward and willing to be part of study were included. Doctors with presence of co-morbidities like diabetes, hypertension, asthma, obesity, infected with COVID-19 and not willing were excluded. Ethical clearance for the study was obtained from the institution prior to initiation of study and consent was taken from all the participants. An online validated questionnaire was shared to participants through Google form and were requested to fill the form. The collected response were analysed using STATA v7 for statistical analysis. Result: Total of 220 participants included in the study, with mean age of 26.75+or-2.69 yrs. among them 87 were female participant and 133 were male participants. On assessment of questionnaire agreed for respective questions as difficulty in decision making (74.6%), difficulty in communication (93.1%), missing simple prescriptions (83.6%), urge to doff (66.4%), headache (78.1%), difficulty in writing (69.1%), and difficulty in seeing (70%). Conclusion: In present study we documented higher incidence of the physical dysfunction and neurological dysfunction among the doctors worked in COVID-19 care associated with use of PPE.

Analysis of the diagnosis and treatment of patients with COVID-19 at a temporary infection hospital deployed in a multidisciplinary city hospital

The novel coronavirus infection COVID-19, caused by SARS-COV-2, has been a global health problem for three years now. A new challenge is virus mutations that change clinical manifestations and response to therapy. Aim. The aim of the workwas to assess the condition of patients with COVID-19 treated in a temporary infectious diseases hospital deployed in a non-infectious multidisciplinary hospital and to identify factors influencing the outcomes of this disease through a retrospective analysis of clinical observations. Material and methods. An analysis of the condition of 92 patients with COVID-19 (ICD-10 codes U07.1 and U07.2) treated in a temporary infectious diseases hospital deployed on the basis of a multidisciplinary hospital is presented. To collect information, the COVIZ program was designed with subsequent export of depersonalized data to the SPSS-18 statistical package. 64 patients recovered and 28 had a fatal outcome. Results and discussion. The work results showed a change in the routing of patients, with a predominance of only patients with a severe course in the hospital. The more frequent prescription of glucocorticosteroids and anti-cytokine drugs also changed the data processing results due to the small number of "control" groups that did not receive these drugs in the hospital. The use of anti-cytokine therapy (levilimab or olokizumab) was more effective in patients younger than 60 years, but in general, 89.1% of those who recovered received these drugs, and 75% of those who died. The data obtained confirmed the high efficiency of early use of subcutaneous anticoagulants and the low efficiency of antibiotic therapy at the stages before the intensive care unit. The frequency of prescribing antibacterial drugs in the dead was 76.8%, and in those who recovered - 57.8%, while later than 8 days from the onset of the disease they were prescribed in 81.8% and 45.9% of cases, respectively (X2=7.357;d.f.=1, p < 0.01, TcF=0.006, OR=5.294 CI 1.499-18.695). Conclusion. It was concluded that the clinical picture and the effectiveness of ongoing therapy require constant monitoring and analysis to optimize the updated treatment regimens for COVID-19.

Principles of glucocorticosteroid administration in patients with COVID-19

Introduction. This article discusses the treatment of coronavirus infection (COVID-19) with glucocorticosteroid drugs (GCS), side effects of drugs and their prevention, transfer from intravenous to intramuscular and then to oral administration, and the development of withdrawal syndrome. The article describes the conditions under which antibiotic therapy is prescribed, as well as the conditions under which the combined use of corticosteroids and antibiotics is necessary. Aim. The aim to analyze the basic principles of corticosteroids prescribing in the treatment of COVID-19: indications for corticosteroids administration, administration regimens and required dosages, side effects of corticosteroids administration. Material and methods. The article uses data from the Interim Guidelines for the Prevention, Diagnosis and Treatment of New Coronavirus Infection (COVID-19), the Federal Clinical Guidelines for the Specialty "Rheumatology", as well as using the literature on basic and clinical endocrinology, cardiology and pharmacology. The work was written using a systems approach, methods of analysis, induction and observation. Results and discussion. Systemic corticosteroids are used in cases of severe and critical course of the disease COVID-19 (confirmation may be an increase in ferritin, procalcitonin, C-reactive protein (CRP), decreased cognitive functions, development of sopor). Their appointment is also justified when the initial course of the disease was not diagnosed as severe, but suddenly the patient's condition deteriorated. The use of antibiotic therapy is advisable when a bacterial infection is attached - (procalcitonin (PCT) > 0.5 ng / ml, purulent sputum, leukocytosis> 12 x 109 / L (in the absence of previous use of glucocorticoids), an increase in band neutrophils of more than 10%). In the presence of chronic infectious diseases in patients with COVID-19 (for example, chronic obstructive pulmonary disease-COPD, chronic pyelonephritis, etc.), antibiotics are prescribed to prevent exacerbations of these diseases. Conclusion. In the course of the study, the authors of the article formulated the following principles of glucocorticoid therapy: drugs should be prescribed according to strict indications;maximum doses are applied in a short course;when the patient's condition is stabilized, it is necessary to reduce the dose in a timely manner and gradually to complete withdrawal to prevent the development of "withdrawal" syndrome, adrenal insufficiency of central genesis, sympathoadrenal crises;during and after treatment, prevention of complications of glucocorticoid therapy (hyperglycemia, hypocalcemia, osteopenia, inflammatory diseases of the urinary system) is recommended;collegial management of patients by infectious diseases and endocrinologists is mandatory.

Physician Autonomy at Issue if Patients Demand Ineffective Treatments

The article describes how physician autonomy is at issue if patients demand ineffective treatments as indicated in a Wisconsin Supreme Court case which centers on whether physicians can be legally required to provide ivermectin for COVID-19 if a patient or family requests it, citing the ethical obligations to consider.

Psychotropic consumption before and during COVID-19 in Asturias, Spain.

BACKGROUND: Spain as multiple other countries has been experiencing an increasing and sustained trend in the use of psychotropic medications since the mid 90s. Recent studies show public health measures implemented to control SARS-Cov2, such as mobility restrictions and the shutdown of nonessential activities increased mental suffering, even contributing to a higher number of anxiety, depression and insomnia disorders that could lead to an increase in the consumption of psychotropics. The aims were: 1) Evaluate the temporal trend in psychotropic consumption by pharmacological subgroup, sex, and age group 2) Estimate the effect of the COVID-19 pandemic in the use of psychotropic drugs. METHODS: We conducted a retrospective observational study, retrieving all prescriptions of anxiolytics, hypnotics and sedatives, and antidepressants dispensed in pharmacies of Asturias (Northern Spain) for Primary Care patients for the period 2018-2021. We presented the data expressed in Daily Defined Doses (DDDs) for 1000 persons/day (DHD). To estimate changes in DHDs by year and age group we conducted two multiple linear regressions (one for males and one for females) for every pharmacological subgroup studied. Changes were considered statistically significant when the regression coefficient was p < 0.05. We used the Software R 4.1.0. RESULTS: For the studied period, the highest DHDs are for antidepressants, although all of the subgroups experienced an increase in consumption rates. Women consumed more psychotropic drugs than men. In 2021, 372 out of every 1000 women were taking daily 1 DDD of these drugs versus 184 out of every 1000 men. Consumption rates for all psychotropic drugs progressively increases with age. Conversely, the biggest increases in consumption were among the youngest age groups (0-14 and 15-29 years) for women, while for men there is more variability. The regression models suggest an upward trend in psychotropic consumption during all the period, especially remarkable from 2020, for both genders and all age groups. CONCLUSIONS: - The consumption of psychotropic drugs has gradually increased over the last 4 years, with a significant boost starting in 2020 for both sexes, matching the start of the SARS-COV2 pandemic and the implementation of strict Public Health measures to contain it. - The increase observed on children and adolescents is a matter of concern.

[Impact of COVID-19 lockdown on the prescription of benzodiazepines]. / Impacto del confinamiento por COVID-19 en la prescripción de benzodiacepinas.

OBJECTIVE: To evaluate the effect of COVID-19 lockdown on the prescription of benzodiazepines by gender, age and district health departments. DESIGN: Longitudinal observational study. LOCATION: Primary care. Asturias (Spain) health district V. PARTICIPANTS: People over 15 years of age with filled benzodiazepine prescriptions in between 2017 and 2020. MAIN MEASUREMENTS: Benzodiazepine DHD (defined daily dose per 1000 habitants) mean difference between the period defined as pre-lockdown and lockdown. Additionally, the difference was adjusted for gender, sex and district health department and also with the interaction among them. RESULTS: DHD mean pre-lockdown was 131.3 and 139.5 in the lockdown; this difference was significant in the global analysis (95% CI: 4.1-12.1). There was an increase in the DHD mean in the 60-74 age group (95% CI: 2.28-21.42), in the group over 90 years old (95% CI: 21.31-40.63) and in women (95% CI: 3.51-14.59). Finally, a decrease in the DHD mean of V11 (95% CI: -29 to -0.66) and V14 (95% CI: -54.28 to -25.04) district health departments was observed. CONCLUSIONS: Certain subgroups show a change in the pattern of benzodiazepine prescription without being able to relate this to the lockdown. We believe that there could be some inertia in the prescription of psychiatric medication according to the biopsychosocial characteristics of the patients; it is important to detect this in order to avoid the medicalization of psychological disorders.

The Association between COVID-19 and Changes in Opioid Prescribing Patterns and Opioid-Related Overdoses: A Retrospective Cohort Study.

Background: Recent data suggest that restrictions related to COVID-19 resulted in changes in the prescribing patterns of opioids. Aims: We sought to analyze Ontario health data for changes in frequencies among new and continuing users for the following opioid prescription characteristics: the type of opioid, the average daily dose, and the prescriber's specialty. Methods: Utilizing data on the Ontario Health Data Platform, we defined two 149-day windows as "before" and "after" based on the initial COVID-19 provincial lockdown. A total of 882,268 individuals met our inclusion criteria and were classified as either "new" or "continuing" users. Chi-square tests and Fisher's exact tests were applied for each level of our primary outcomes to determine whether there were significant changes in prescription proportions before and after the lockdown. Results: A decline of 28% was observed for the number of new users after the lockdown. Statistically significant changes were observed for new users across almost all opioid prescription characteristics between the before and after windows. The proportion of new users who received at least one dispensing event from a pharmacist increased by 26.32%, whereas continuing users increased by 378.61%. There were no statistically significant shifts in opioid prescriptions among individuals with a reported toxicity event during the study period. Conclusions: In terms of opioid prescribing patterns, new users experienced greater change following the onset of the pandemic lockdown than continuing users. Our findings potentially showcase the unintended impacts that COVID-19-related restrictions had on non-COVID-19-related health services, which can inform future policy decisions.

Contexte: Des données récentes indiquent que les restrictions liées à la COVID-19 ont entrainé des changements dans la prescription des opioïdes.Objectifs: Nous avons cherché à analyser les données sur la santé de l'Ontario pour déceler les changements de fréquence chez les nouveaux utilisateurs et les utilisateurs prévalents pour les caractéristiques de prescription d'opioïdes suivantes : le type d'opioïde, la dose quotidienne moyenne, et la spécialité du prescripteur.Méthodes: En utilisant les données de la plateforme de données sur la santé de l'Ontario, nous avons défini deux fenêtres de 149 jours comme suit : « avant ¼ et « après ¼ le confinement provincial initial de la COVID-19. Un total de 882 268 personnes ont répondu à nos critères d'inclusion et ont été classées comme « nouveaux utilisateurs ¼ ou « utilisateurs prévalents ¼. Des tests de chi-carré et des tests exacts de Fisher ont été appliqués pour chaque niveau de nos résultats primaires afin de déterminer s'il y avait eu des changements importants dans les proportions prescrites avant et après le confinement.Résultats: Une baisse de 28 % a été observée pour le nombre de nouveaux utilisateurs après le confinement.Des changements statistiquement significatifs ont été observés pour les nouveaux utilisateurs pour presque toutes les caractéristiques de prescriptions d'opioïdes entre les fenêtres avant et après. La proportion de nouveaux utilisateurs ayant eu au moins une prescription remplie par un pharmacien a augmenté de 26,32 %, tandis que le nombre d'utilisateurs prévalents a augmenté de 378,61 %. Il n'y a pas eu de changements statistiquement significatifs dans les prescriptions d'opioïdes parmi les personnes ayant déclaré un évènement de ⁠toxicité au cours de la période d'étude.Conclusions: En matière de modèles de prescription d'opioïdes, les nouveaux utilisateurs ont connu un changement plus important après le début du confinement de la pandémie que les utilisateurs prévalents. Nos résultats démontrent possiblement les répercussions inattendues des restrictions liées à la COVID-19 sur les services de santé non liés à la COVID-19, ce qui pourrait éclairer les décisions politiques futures.